• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Patients and experiences from the first Danish flavour clinic.
CONCLUSIONS: An accurate distinction between smell and taste requires application of validated chemosensory tests and specialised knowledge. As this is not readily available in all ENT clinics, sensory loss without a clear aetiology should be referred to a more specialisedcentre. FUNDING: none. TRIAL REGISTRATION: not relevant. PMID: 33576332 [PubMed - in process]
Source: Danish Medical Journal - February 14, 2021 Category: General Medicine Tags: Dan Med J Source Type: research

Characterisation of patients with idiopathic olfactory dysfunction and plan for clinical follow-up.
CONCLUSIONS: Patients suffering from idiopathic OD were predominantly females with a long symptom duration. Only few of these patients suffered from allergies or sino-nasal pathologies. Patient history, the Sino-Nasal Outcome Test and threshold discrimination identification scores from the Extended Sniffin Sticks test are the most valuable clinical tools for diagnosing the aetiology behind OD. An ideal workup for idiopathic OD is presented. FUNDING: none. TRIAL REGISTRATION: not relevant. PMID: 33215598 [PubMed - in process]
Source: Danish Medical Journal - November 21, 2020 Category: General Medicine Tags: Dan Med J Source Type: research